MGI and SuperGen’s Dacogen accepted for review
The new drug application (NDA) for Dacogen (decitabine) injection was submitted to the FDA on November 1, 2004. The acceptance for review of the NDA represents the FDA’s
The new drug application (NDA) for Dacogen (decitabine) injection was submitted to the FDA on November 1, 2004. The acceptance for review of the NDA represents the FDA’s
Orathecin (rubitecan) capsules is SuperGen’s investigational drug for the treatment of pancreatic cancer patients who have failed at least one prior chemotherapy regimen. SuperGen’s decision to withdraw the
The new funds will be used to continue the clinical development of Neuro3d’s broad pipeline of innovative drug candidates targeting psychiatric disorders such as schizophrenia, depression and anxiety,
Lyrica (pregabalin capsules) have received FDA approval for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved
APD356 is a selective agonist of 5-HT2C serotonin receptors, which are concentrated in the hypothalamus, an area of the brain known to play an important role in regulating
The formulation for Wellbutrin XL (bupropion hydrochloride extended-release tablets) was developed by Biovail, which licensed the product’s worldwide (excluding Canada) sales and distribution rights to GlaxoSmithKline in October
OXi4503 has been shown in animals to have potent anti-tumor activity as both a single-agent and in combination therapy. This phase I trial propels OxiGene forward into the
The MannKind pulmonary insulin system rapidly delivers regular human insulin to the bloodstream in a manner that approximates the first phase insulin release spike by the pancreas that
Under the terms of the agreement, Bristol-Myers Squibb will receive exclusive distribution rights to commercialize Emsam (selegiline transdermal system), if approved, in the US and Canada, with an
Results from the study reveal that injected paclitaxel appear to restore nerve function in an animal model. In the study, it was demonstrated that low and medium doses